CSCC_ASC Therapy in Patients With Severe Heart Failure

NCT02387723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-02-02

No results posted yet for this study

Summary

The present aim is to perform at small clinical safety trial in heart failure patients with allogeneic adipose tissue derived mesenchymal stem cells.

Conditions

Interventions

BIOLOGICAL

Allogeneic adipose derived stem cells (CSCC_ASC)

Culture expanded allogeneic adipose derive stem cells (CSCC\_ASC)

Sponsors & Collaborators

  • JKastrup

    lead OTHER

Principal Investigators

  • Jens Kastrup, Professor MD · Rigshospitalet, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02387723 on ClinicalTrials.gov